Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Quark Pharmaceuticals to advance siRNA QPI-1002 into clinical studies

Jan. 11, 2010

Ono and Kyorin submit NDAs for orally disintegrating imidafenacin

Jan. 8, 2010

Keryx announces SPA agreement with FDA on phase III Zerenex trials in ESRD

Jan. 7, 2010

Mitsubishi Tanabe Pharma discloses novel BK and maxi K+ channel openers

Dec. 30, 2009

Pfizer's Toviaz superior to Detrol LA in treating urge urinary incontinence

Dec. 21, 2009

AEterna Zentaris reports results from phase III Z-036 efficacy trial of cetrorelix in BPH

Dec. 10, 2009

Merck & Co. describes beta3-adrenoceptor agonists for urinary incontinence

Dec. 4, 2009

Sitaxentan reduces post-CPB acute kidney injury in porcine model

Dec. 3, 2009

Novartis claims MMP inhibitors for the treatment of Alport syndrome

Dec. 2, 2009

Genzyme reports results from phase II/III trial of GENZ-644470 in hyperphosphatemia

Nov. 19, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...